A Phase 2 interventional study of 2.0 mg DE-122 Injectable Solution + Lucentis and 4.0 mg DE-122 Injectable Solution + Lucentis in Age-Related Macular Degeneration, sponsored by Santen Inc.. Completed at 14 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-07-13.
Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 57th largest by enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2017, is one of 24 in phase 2, and was the 109th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Santen Inc., one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen Inc. is the lead sponsor of 32 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Santen Pharmaceutical Co., Ltd. has 6 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
[Ocular]
[Non-ocular]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.0 mg DE-122 and Lucentis ® 0.5 mg
Drug: 2.0 mg DE-122 Injectable Solution + Lucentis
4.0 mg DE-122 and Lucentis ® 0.5 mg
Drug: 4.0 mg DE-122 Injectable Solution + Lucentis
Sham and Lucentis ® 0.5 mg
Drug: Lucentis
Drug pages: Carotuximab · Ranibizumab
Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
Drug pages: Carotuximab · Ranibizumab
Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24
BCVA is the primary efficacy variable for this study, and mean change from baseline in BCVA at Week 24 is the primary efficacy endpoint. An increase in the number of letters read correctly means that vision has improved.The lower the number of letters read correctly on the eye chart, the worse the vision.
Time frame: Week 24
| Milestone | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 |
|---|---|---|---|
| Started | 17 | 31 | 28 |
| Completed | 16 | 30 | 25 |
| Not completed | 1 | 1 | 3 |
BCVA is the primary efficacy variable for this study, and mean change from baseline in BCVA at Week 24 is the primary efficacy endpoint. An increase in the number of letters read correctly means that vision has improved.The lower the number of letters read correctly on the eye chart, the worse the vision.
| letters | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 |
|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24 | 4.35 ± 8.937 | 0.87 ± 11.485 | -1.70 ± 10.550 |
Collected over From Inform consent to the end of the study at week 32.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sham | 0/17 (0%) | 1/17 (5.9%) | 5/17 (29.4%) |
| 2.0 mg DE-122 | 0/31 (0%) | 1/31 (3.2%) | 10/31 (32.3%) |
| 4.0 mg DE-122 | 1/28 (3.6%) | 4/28 (14.3%) | 10/28 (35.7%) |
| Event | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/17 | 1/31 | 0/28 |
| Subretinal fluidEye disorders | 0/17 | 0/31 | 1/28 |
| Cardiac arrestCardiac disorders | 0/17 | 0/31 | 1/28 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/17 | 0/31 | 1/28 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/17 | 0/31 | 1/28 |
| CataractEye disorders | 0/17 | 1/31 | 0/28 |
| Event | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 |
|---|---|---|---|
| Conjunctival hyperaemiaEye disorders | 0/17 | 2/31 | 4/28 |
| Eye painEye disorders | 0/17 | 4/31 | 1/28 |
| Conjunctival haemorrhageEye disorders | 2/17 | 3/31 | 0/28 |
| Retinal haemorrhageEye disorders | 0/17 | 3/31 | 3/28 |
| Eyelid oedemaEye disorders | 0/17 | 1/31 | 3/28 |
| Conjunctival oedemaEye disorders | 0/17 | 1/31 | 2/28 |
| Erythema of eyelidEye disorders | 0/17 | 1/31 | 2/28 |
| Visual impairmentEye disorders | 0/17 | 1/31 | 2/28 |
| HeadacheNervous system disorders | 0/17 | 0/31 | 2/28 |
| Intraocular pressure increasedInvestigations | 0/17 | 2/31 | 1/28 |
| Age, Continuous(years) | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 | Total |
|---|---|---|---|---|
| Mean | 75.4 ± 9.18 | 72.1 ± 7.34 | 75.6 ± 9.84 | 74.1 ± 8.79 |
| Sex: Female, Male(Participants) | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 | Total |
|---|---|---|---|---|
| Female | 12 | 14 | 15 | 41 |
| Male | 5 | 17 | 13 | 35 |
| Race (NIH/OMB)(Participants) | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 9 | 9 | 4 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 8 | 20 | 24 | 52 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sham | 2.0 mg DE-122 | 4.0 mg DE-122 | Total |
|---|---|---|---|---|
| United States | 9 | 22 | 25 | 56 |
| Philippines | 8 | 9 | 3 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Dec 2019, 29 months.
Results were first posted in Jul 2021, 1 year 6 months after primary completion. A results delay was requested in Sep 2020.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 29 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carotuximab · Ranibizumab